Kirk B Jensen

Title: Kirk B Jensen: Pioneering Innovations in Nucleic Acid Ligands

Introduction:

Kirk B Jensen, a prominent inventor hailing from Boulder, CO (US), has made significant contributions to the field of nucleic acid ligands. With a track record of 14 patents in his name, Jensen's groundbreaking research in systematic evolution of ligands by exponential enrichment has revolutionized methods for obtaining nucleic acid ligands. This article explores his latest patents, career highlights, collaborative efforts, and the impact of his work on the field of molecular biology.

Latest Patents:

Jensen's recent patents focus on variations of the photoSELEX (Systematic Evolution of Ligands by Exponential Enrichment) method, which enables the development of nucleic acid ligands that can photocrosslink to specific target molecules associated with disease states. These innovative methods allow for the identification and isolation of nucleic acids with affinity to disease-related target molecules. By integrating photocrosslinkable nucleic acids into the candidate mixture, Jensen's inventions facilitate the selective retention of ligands associated with the disease state while removing unwanted affinity to non-disease-related molecules.

Career Highlights:

Throughout his career, Jensen has held positions at respected biotechnology companies, contributing to their research and development efforts. He worked at Nexstar Pharmaceuticals, Inc., where he dedicated his expertise to advancing molecular screening and targeted drug delivery technologies. Later on, at Somalogic, Incorporated, Jensen continued his pioneering work, focusing on the development of aptamer-based diagnostics and therapeutics.

Collaborations:

Jensen had the privilege of collaborating with esteemed industry professionals, including Larry M Gold and Bruce Eaton. Larry M Gold, a co-worker at Somalogic, is a renowned scientist in the field of aptamers and played an instrumental role in the development of the groundbreaking SELEX technology. Bruce Eaton, another notable collaborator, contributed his expertise in the field of molecular biology, further enhancing Jensen's research endeavors.

Conclusion:

Kirk B Jensen's contributions to the field of nucleic acid ligands have laid the foundation for advancements in molecular biology and targeted therapeutics. His patents on systematic evolution of ligands by exponential enrichment have paved the way for innovative methods to identify nucleic acids with affinity to disease-related molecules. Collaborating with renowned professionals in the field, Jensen's work continues to push the boundaries of molecular science and holds tremendous potential for future therapeutic discoveries.